Silo Pharma Inc (SILO) - Total Liabilities
Based on the latest financial reports, Silo Pharma Inc (SILO) has total liabilities worth $1.34 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Silo Pharma Inc - Total Liabilities Trend (2010–2025)
This chart illustrates how Silo Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Silo Pharma Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Silo Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Silo Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiankun International Bhd
KLSE:8923
|
Malaysia | RM53.30 Million |
|
Athena Resources Ltd
AU:AHN
|
Australia | AU$117.32K |
|
LabGenomics Co. Ltd
KQ:084650
|
Korea | ₩76.00 Billion |
|
NEOMETALS LTD SP.ADS/10
F:9R91
|
Germany | €6.10 Million |
|
Palred Technologies Limited
NSE:PALREDTEC
|
India | Rs753.39 Million |
|
ARIP Public Company Limited
BK:ARIP
|
Thailand | ฿51.43 Million |
|
Trinity Freehold & Leasehold PRP Fund
BK:TNPF
|
Thailand | ฿847.93K |
Liability Composition Analysis (2010–2025)
This chart breaks down Silo Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Silo Pharma Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Silo Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Silo Pharma Inc (2010–2025)
The table below shows the annual total liabilities of Silo Pharma Inc from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.30 Million | -45.34% |
| 2024-12-31 | $2.38 Million | +51.51% |
| 2023-12-31 | $1.57 Million | +20.52% |
| 2022-12-31 | $1.30 Million | -8.81% |
| 2021-12-31 | $1.43 Million | +878.24% |
| 2020-12-31 | $145.97K | -71.75% |
| 2019-12-31 | $516.74K | +15.35% |
| 2018-12-31 | $447.98K | +2.20% |
| 2017-12-31 | $438.34K | -3.26% |
| 2016-12-31 | $453.10K | -7.67% |
| 2015-12-31 | $490.76K | +21.91% |
| 2014-12-31 | $402.56K | -3.86% |
| 2013-12-31 | $418.72K | +909.61% |
| 2012-12-31 | $41.47K | +1084.94% |
| 2011-12-31 | $3.50K | -107.37% |
| 2010-12-31 | $-47.48K | -- |
About Silo Pharma Inc
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's … Read more